Quick Takeaways
- This page summarizes Frank Mccormick's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
- 5 reported transactions and 0 derivative rows are listed below.
- Filing timestamp: 31 Oct 2025, 16:38.
Frank Mccormick - 29 Oct 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)
- Role
- Director
- Signature
- /s/ Will Solis, Attorney-in-Fact
- Issuer symbol
- BBIO
- Transactions as of
- 29 Oct 2025
- Net transactions value
- -$13,206,528
- Form type
- 4
- Filing time
- 31 Oct 2025, 16:38:45 UTC
- Previous filing
- 29 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Frank Mccormick filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 31 Oct 2025."
What Changed
- Previous filing in this sequence was filed on 29 Oct 2025.
- Current net transaction value: -$13,206,528.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| MCCORMICK FRANK | Director | C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO | /s/ Will Solis, Attorney-in-Fact | 31 Oct 2025 | 0001257809 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BBIO | Common Stock | Sale | $7,317,315 | -111,755 | -13% | $65.48 | 766,583 | 29 Oct 2025 | By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | F1, F2 |
| transaction | BBIO | Common Stock | Sale | $2,059,749 | -31,116 | -4.1% | $66.20 | 735,467 | 29 Oct 2025 | By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | F1, F3 |
| transaction | BBIO | Common Stock | Sale | $236,130 | -3,497 | -0.48% | $67.52 | 731,970 | 29 Oct 2025 | By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | F1, F4 |
| transaction | BBIO | Common Stock | Sale | $588,985 | -8,598 | -1.2% | $68.50 | 723,372 | 29 Oct 2025 | By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | F1, F5 |
| transaction | BBIO | Common Stock | Sale | $3,004,349 | -43,393 | -6% | $69.24 | 679,979 | 29 Oct 2025 | By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | F1, F6 |
| holding | BBIO | Common Stock | 83,275 | 29 Oct 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024. |
| F2 | Represents the weighted average sale price of the shares sold from $65.00 to $65.999 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F3 | Represents the weighted average sale price of the shares sold from $66.00 to $66.9875 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F4 | Represents the weighted average sale price of the shares sold from $67.00 to $67.996 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F5 | Represents the weighted average sale price of the shares sold from $68.005 to $68.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F6 | Represents the weighted average sale price of the shares sold from $69.00 to $69.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |